BioCardia Regains Full Compliance with Nasdaq Listing Requirements
September 18, 2024 08:30 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
September 09, 2024 16:05 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
August 30, 2024 08:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family
August 29, 2024 08:30 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment
August 21, 2024 07:00 ET
|
BioCardia, Inc.
BioCardia announced today that the FDA has approved an important protocol amendment for the CardiAMP Heart Failure II Trial, its confirmatory Phase 3 trial
BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results
August 13, 2024 16:30 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024
August 07, 2024 07:00 ET
|
BioCardia, Inc.
BioCardia will provide a Q2 2024 corporate update and report its financial results by conference call on Tuesday August 13, 2024
BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family
July 30, 2024 07:00 ET
|
BioCardia, Inc.
BioCardia, Inc., today reported it has submitted a 510(k) for approval of its patented Morph® DNA™ Steerable Introducer Sheath with the FDA.
Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure
July 25, 2024 07:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application
July 17, 2024 07:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...